Patent intelligence · US
US 6426076
Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy
Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy
Patent details — US 6426076
- Jurisdiction
- US
- Status
- expired
- Grant date
- Jul 30, 2002
- Expiration
- Jul 25, 2022
- Applicant
- PASCO Pharmazeutische Präparate GmbH
- Claims
- 14
- CPC classes
- A61K, A61K31/375, A61K31/40, A61K31/475
Quick answer
US 6426076 (Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy) is held by PASCO Pharmazeutische Präparate GmbH. Status: expired. Granted Jul 30, 2002. Expires Jul 25, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Key facts
- Applicant
- PASCO Pharmazeutische Präparate GmbH
- Grant date
- Expiration
- Claims
- 14
- CPC classes
- A61K, A61K31/375, A61K31/40, A61K31/475, A61K31/505, A61K31/70
More from PASCO Pharmazeutische Präparate GmbH
Related pharmaceutical patents in our USPTO index.
-
US 12310943
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12297182
Compositions comprising an urolithin compound
granted -
US 12226455
Medical composition for treating cardiac wasting and cachexia
granted -
US 12220424
Compositions comprising nicotinamide riboside and a urolithin
granted -
US 12109190
Urolithins as immune response enhancers
granted -
US 12036205
Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders
granted -
US 12030863
Prodrugs of urolithins and uses thereof
granted -
US 11969408
Method for improving mitophagy in subjects
granted
Frequently asked questions
What is US patent 6426076?
US 6426076 (Ascorbic acid as an adjuvant in the treatment of malignant tumors using chemotherapy and radiotherapy) is held by PASCO Pharmazeutische Präparate GmbH. Status: expired. Granted Jul 30, 2002. Expires Jul 25, 2022 (0 years remaining) — relevant for patent-cliff and LOE planning.
Who owns US 6426076?
PASCO Pharmazeutische Präparate GmbH is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 60 pharmaceutical patents for this assignee.
When does US 6426076 expire?
Our index shows an expiration date of Jul 25, 2022 (0 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.